To evaluate health-related quality of life ( HRQOL ) and corticosteroid use in patients with moderate to severely active SLE enrolled in two international , multicentre , randomized controlled trials of epratuzumab ( ALLEVIATE-@ and -@ ) and a long-term extension study ( SL@ ) .